Pravastatin as a Prophylactic to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 27, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

March 5, 2025

Conditions

Hematopoietic Stem Cell Transplant (HSCT)Endothelial Injury

Interventions

DRUG

Pravastatin

Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.

Trial Locations (1)

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors

lead

Children's Hospital Medical Center, Cincinnati

OTHER